CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25 janv. 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
24 mars 2022 06h30 HE
|
LAVA Therapeutics N.V.
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 déc. 2021 10h06 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph...
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 déc. 2021 07h00 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
11 nov. 2021 10h08 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...
LAVA Therapeutics Expands Management Team with Three Key Appointments
09 nov. 2021 06h30 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
Stingthera, Inc. Announces Clinical Collaboration with Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
03 nov. 2021 06h45 HE
|
Stingthera, Inc.
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Stingthera, Inc. today announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada)...
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
02 nov. 2021 07h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
09 déc. 2020 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE’s Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation
28 sept. 2020 06h30 HE
|
CENTOGENE GmbH
Company awarded ISO 27001 Accreditation for its Information Security Management SystemThe internationally recognized certification is set by the International Organization for Standardization (ISO),...